France
· Delayed Price · Currency is EUR Acticor Biotech SAS Company Description
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases.
The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI.
It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19).
The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks.
The company was incorporated in 2013 and is headquartered in Paris, France.
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Gilles Avenard |
Contact Details
Address: HOpital Bichat Paris, 75018 France | |
| Phone | 33 6 76 23 38 13 |
| Website | acticor-biotech.com |
Stock Details
| Ticker Symbol | ALACT |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0014005OJ5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yannick Pletan M.D., M.Sc. | Deputy Chief Executive Officer, GM and Chief Medical Officer |
| Sophie Lebel-Binay Ph.D. | Deputy Chief Executive Officer, Chief Scientific Officer and GM |
| Dr. Gilles Avenard M.D. | Founder, Chief Executive Officer and Director |
| Philippe Billiald Ph.D., Pharm.D. | Scientific Founder |
| Martine Jandrot-Perrus M.D., Ph.D. | Scientific Founder |
| Francois Guillet | Chief Financial Officer |
| Elie Toledano | Head of Scientific Affairs and Business Intelligence |
| Adeline Meilhoc | Head of Global Clinical Development |
| Anouar Sari | Head of Clinical Operations |